E-DA HealthCare Group | E-DA Cancer Hospital

Research site

(Unclaimed)

Location

No.21, Yi-Da road, Jiao-Su Village, Yan-Chao Dist., Kaohsiung city, Kaohsiung, Taiwan

Site insights

Top conditions

Top treatments

Ropeginterferon Alfa-2b

Erdafitinib

Docetaxel

Livmoniplimab

Budigalimab

Hydroxyurea

Sacituzumab

P1101

Anagrelide

Telisotuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 7 total trials

Locations recently updated

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)

The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with...

Active, not recruiting

Advanced Solid Tumor

Drug: Erdafitinib

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling

Non Small Cell Lung Cancer

Drug: Docetaxel

Biological: Telisotuzumab Vedotin

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance (SURPASS ET)

This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101...

Active, not recruiting

Essential Thrombocythemia

Drug: Anagrelide

Biological: Ropeginterferon alfa-2b

Status recently updated

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Enrolling

Active, not recruiting

Triple Negative Breast Cancer

PD-L1 Negative

Drug: Sacituzumab Govitecan-hziy

Drug: Paclitaxel

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events...

Enrolling

Platinum Resistant High Grade Epithelial Ovarian Cancer

Hepatocellular Carcinoma

Drug: Itraconazole (ITZ)

Drug: ABBV-400

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-1)

Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presentin...

Active, not recruiting

Hepatocellular Carcinoma

Drug: Sorafenib

Drug: Livmoniplimab

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms